{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:39:23Z","timestamp":1770892763661,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Serum ferritin (Ft) reflects total body iron stores and serves as a reference indicator for iron supplementation. However, optimal Ft level remains unclear in hemodialysis (HD) patients. We previously reported that total body iron (TBI), a novel index defined as the sum of red blood cell iron and storage iron, increases during oral iron replacement therapy (OIRT) and remains stable once iron sufficiency is achieved. In this study, we analyzed data from 100 OIRT courses in 79 maintenance HD patients. We examined the relationship between changes in hemoglobin (Hb) and Ft (\u22bfHb, \u22bfFt) at 4 and 7 months after the initiation of OIRT, during which TBI remained stable, to determine the Ft level required for erythropoiesis. At 7 months, compared with 4 months, mean Hb significantly decreased by 0.2 g\/dL (p = 0.03), while median Ft significantly increased from 60 to 75.0 ng\/mL (p &lt; 0.01). After adjustment for TBI, a significant inverse relationship was observed between \u22bfHb and \u22bfFt (\u03b2 = \u221235.9, 95% CI \u221240.1 to \u221231.7, p &lt; 0.001). These results indicate that an increase of 1 g\/dL in Hb requires approximately 30\u201340 ng\/mL of Ft, suggesting that this threshold may be useful for guiding iron supplementation in the treatment of anemia.<\/jats:p>","DOI":"10.3390\/ijms27041754","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:48:34Z","timestamp":1770889714000},"page":"1754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the Threshold of Serum Ferritin Required for Erythropoiesis and Iron Sufficiency in Hemodialysis Patients"],"prefix":"10.3390","volume":"27","author":[{"given":"Chie","family":"Ogawa","sequence":"first","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"},{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Morito","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-8116","authenticated-orcid":false,"given":"Naohisa","family":"Tomosugi","sequence":"additional","affiliation":[{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"},{"name":"Division of Systems Bioscience for Drug Discovery Project Research Center, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunimi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2026). Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int., 109, S1\u2013S99.","DOI":"10.1016\/j.kint.2025.06.006"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Ren. Replace. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ogawa, C., Tsuchiya, K., Tomosugi, N., and Maeda, K. (2024). High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031508"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/ndt\/gfad096","article-title":"Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease","volume":"38","author":"Hasegawa","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000543888","article-title":"Association between serum iron store biomarkers and all-cause mortality in Japanese patients undergoing hemodialysis: A nationwide cohort study","volume":"56","author":"Nishiwaki","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Eisenga, M.F., Nolte, I.M., van der Meer, P., Bakker, S.J.L., and Gaillard, C.A.J.M. (2018). Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1021-3"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00277-023-05198-2","article-title":"A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia","volume":"102","author":"Jongkraijakra","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2017.6846","article-title":"Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children with Nutritional Iron-Deficiency Anemia","volume":"317","author":"Powers","year":"2017","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-87-6-710","article-title":"Iron balance in hemodialysis patients","volume":"87","author":"Eschbach","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_12","unstructured":"World Health Organization (2020). WHO Guideline on Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations, World Health Organization."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kuragano, T., Kitamura, K., Matsumura, O., Matsuda, A., Hara, T., Kiyomoto, H., Murata, T., Fujimoto, S., Hase, H., and Joki, N. (2016). ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147328"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/kisup.2015.6","article-title":"Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry","volume":"5","author":"Hamano","year":"2015","journal-title":"Kidney Int. Suppl."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Takasawa, K., Takaeda, C., Wada, T., and Ueda, N. (2018). Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders. Nutrients, 10.","DOI":"10.3390\/nu10040428"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2169\/internalmedicine.8520-16","article-title":"Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis","volume":"56","author":"Sanai","year":"2017","journal-title":"Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"on behalf of the FIND-CKD Study Investigators. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2020.06.046","article-title":"AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia","volume":"159","author":"Ko","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","article-title":"British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults","volume":"70","author":"Snook","year":"2021","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17900","article-title":"A British Society for Haematology Good Practice Paper. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children","volume":"196","author":"Fletcher","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000312381","article-title":"Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation","volume":"31","author":"Kuragano","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tomosugi, N., Koshino, Y., Ogawa, C., Maeda, K., Shimada, N., Tomita, K., Daimon, S., Shikano, T., Ryu, K., and Takatani, T. (2023). Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25 in Hemodialysis Patients: A Prospective, Multicenter, Observational Riona-Oral Iron Absorption Trial. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202308.1352.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/trf.13659","article-title":"National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Effect of iron supplementation on iron stores and total body iron after whole blood donation","volume":"56","author":"Cable","year":"2016","journal-title":"Transfusion"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","article-title":"Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System","volume":"108","author":"Tomosugi","year":"2006","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:49:51Z","timestamp":1770889791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041754"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041754","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}